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Abstract
Background: It is currently unknown whether bone erosion in gout occurs through an ‘inside-out’ mechanism due
to direct intra-osseous crystal deposition or through an ‘outside-in’ mechanism from the surface of bone. The aim
of this study was to examine the mechanism (‘outside-in’ vs. ‘inside-out’) of monosodium urate (MSU) crystal
deposition in bone erosion in gout. Specifically, we used three-dimensional dual-energy computed tomography
(DECT) to analyse the positional relationship between bone and MSU crystal deposition in tophaceous gout, and to
determine whether intra-osseous crystal deposition occurs in the absence of erosion.
Methods: One hundred forty-four participants with gout and at least one palpable tophus had a DECT scan of
both feet. Two readers independently scored all metatarsal heads (1433 bones available for scoring). For bones in
contact with urate, the bone was scored for whether urate was present within an erosion, on the surface of bone
or within bone only (true intra-osseous deposit). Data were analysed using generalised estimating equations.
Results: Urate in contact with bone was present in 370 (54.3 %) of 681 joints with urate deposition. For those
bones in contact with urate, deposition was present on the surface of bone in 143 (38.6 %) of 370 joints and within
erosion in 227 (61.4 %) of 370. True intra-osseous urate deposition was not observed at any site (p < 0.0001). For all
bones with apparent intra-osseous deposition in one plane, examination in other planes revealed urate deposition
within an en face erosion.
Conclusions: In tophaceous gout, MSU crystal deposition is present within the joint, on the bone surface and
within bone erosion, but it is not observed within bone in the absence of a cortical break. These data support the
concept that MSU crystals deposit outside bone and contribute to bone erosion through an ‘outside-in’ mechanism.
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Background
Bone erosion is a frequent consequence of tophaceous
gout. Advanced imaging techniques such as conven-
tional computed tomography and magnetic resonance
imaging have demonstrated a close relationship between
tophus and bone erosion [1, 2]. The tophus is an orga-
nized structure consisting of monosodium urate (MSU)
crystals and chronic inflammatory tissue [3]. Dual-
energy computed tomography (DECT) is a recently
developed imaging method that allows non-invasive de-
tection of urate [4]. DECT studies have also shown a
close relationship between bone erosion and MSU crys-
tal deposition in tophaceous gout [5].
Bone erosion occurs in other forms of inflammatory
arthritis, including rheumatoid arthritis (RA). Histo-
logical and imaging studies have implicated both inva-
sion of inflamed synovial tissue or pannus into bone
(‘outside-in’) and cytokine-mediated osteitis visualized as
bone marrow oedema (‘inside-out’) as potential mecha-
nisms for bone erosion in RA [6–8].
Some investigators have postulated that MSU crystals
can form within the Haversian canals, leading to true
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intra-osseous deposition [9]. However, in joints affected
by gout, MSU crystals are observed primarily within
synovial fluid, synovium, articular cartilage, and bone in
the subchondral region [10]. Histological analysis of
joints affected by gout show that MSU crystals are
frequently deposited at the surface of cartilage [10].
Similarly, in imaging studies using high-resolution
ultrasonography, the double-contour sign is frequently
observed; this sign is thought to represent MSU crystals
coating the articular cartilage [11]. Collectively, path-
ology and imaging observations support the concept
that bone erosion in gout occurs through an ‘outside-
in’ mechanism whereby MSU crystals deposit on the
surface of articular cartilage surface or within synovium
and then interact with bone cells to develop erosion. If
this is the case, we would anticipate that MSU crystals
would be present both on the surface of bone and
within bone erosion, but that intra-osseous MSU crystal
deposition without a cortical break (erosion) would not
occur.
The aim of this study was to examine the mechanism
(‘outside-in’ vs. ‘inside-out’) of MSU crystal deposition in
bone erosion in gout. Specifically, we used three-
dimensional DECT imaging to analyse the positional re-
lationship between bone and MSU crystal deposition in
tophaceous gout, and to determine whether intra-
osseous crystal deposition occurs in the absence of
erosion.
Methods
One hundred forty-four people with tophaceous gout
were prospectively recruited from rheumatology clinics
in Auckland, New Zealand. All participants had gout ac-
cording to the 1977 American Rheumatism Association
classification criteria [12] and at least one palpable to-
phus found in a clinical examination. The New Zealand
Ministry of Health Ethics Committee approved this
study. All participants provided written informed con-
sent before inclusion in the study.
DECT scans of the feet were performed using a dual-
x-ray tube 128 detector row scanner (SOMATOM Def-
inition Flash; Siemens Medical, Erlangen, Germany). The
patients were positioned feet first in a supine position
with the feet in a plantar flexion position. The scan was
acquired in a craniocaudal direction, starting proximally
5 cm from the ankle joint to the toe tips. Both ankles
and feet were scanned axially in one helical acquisition.
All scans were taken with the same image protocol: ac-
quisition at 128 × 0.6 mm and pitch of 0.7. X-ray tube 1
was operated at 80 kV/260 mA and tube 2 at 140 kV/
130 mA. The images were reconstructed on a bone algo-
rithm, 512 × 512 matrix, into 0.75-mm slices with a 0.5-
mm increment. Additional reconstructions were done
on a soft tissue algorithm, 512 × 512 matrix, also into a
0.75-mm slice with a 0.5-mm increment. The images
were viewed as 0.75-mm slices using a picture archiving
and communication system. A proprietary workstation
(syngo MultiModality Workplace; Siemens Medical) was
used with proprietary software (syngo MMWP VE 36A
2009; Siemens Medical). For the 80-kV images, fluid was
set at 50 Hounsfield units (HU), the ratio for urate at
1.36, minimum HU at 150 and smoothing range at 4.
For the 140-kV images, fluid was set at 50 HU and max-
imum HU at 500.
Two trained readers (PTo and ND) independently
scored all metatarsal heads (1433 bones available for
scoring). Each site was initially scored for the presence
or absence of urate deposition within the joint. If urate
was present within the joint, the presence of urate in
contact with bone was then scored. For bones in contact
with urate, the site was then scored for whether urate
was present within an erosion (a sharply demarcated
area of focal bone loss seen in two planes, with a cortical
break in at least one plane), and if not within an erosion,
on the surface of bone or within bone only (as a true
intra-osseous deposit). In the case of reader disagree-
ment, agreement was reached in a consensus re-scoring
exercise. Pre-consensus inter-reader κ values for all scor-
ing were >0.93.
Data were analysed using SAS version 9.4 software
(SAS Institute Inc., Cary, NC, USA). Means with SDs
and percentages were used to describe the clinical
characteristics of participants. Differences between the
location of urate deposits in each and all metatarsal
heads were modelled taking into account clustering of
results within individuals using generalised estimating
equations and the GENMOD procedure of SAS. Confi-
dence intervals for proportions were calculated by
using Fisher’s exact test with the mid-P method using
www.OpenEpi.com [13]. All tests were two-tailed, and




Participant characteristics are shown in Table 1. Partici-
pants were predominantly men (93.1 %). The mean (SD)
age of the sample was 59 years, and median disease dur-
ation was 22 years. More than half of the participants
were of Māori or Pacific ethnicity. Most (97.3 %) were
receiving urate-lowering therapy. The mean (SD) serum
urate at the time of scanning was 0.40 (0.12) mmol/L.
There were four participants who were not receiving
urate-lowering therapy due to patient preference or in-
tolerance to urate-lowering therapies. These participants
had numerically fewer palpable tophi than the group
overall (median number of tophi 2).
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Positional relationship between bone and MSU crystal
deposition
For all metatarsal heads, urate deposition in the joint
was present in 681 (47.5 %) of 1443 sites (Fig. 1a). Urate
in contact with bone was present in 370 (54.3 %) of 681
joints with urate deposition. For those bones in contact
with urate, deposition was present within erosion in 227
(61.4 %) of 370 joints (Fig. 1b) and on the surface of
bone in 143 (38.6 %) of 370 (Fig. 1c).
True intra-osseous urate deposition was not observed
at any site (compared with deposition in erosions and on
the surface of bone; p < 0.0001). For all bones with ap-
parent intra-osseous deposition in one plane, examin-
ation in other planes demonstrated urate deposition
within an en face erosion (Fig. 2).
Table 2 shows the distribution of urate deposition at
each metatarsal head and at all bone sites. Urate depos-
ition was present most frequently at the first metatarsal
head. Similarly, urate deposition in contact with bone
and at the site of erosion was also most often observed
at the first metatarsal head.
Discussion
This study demonstrates that MSU crystal deposition in
tophaceous gout is present within the joint, on the bone
surface and within bone erosion, but is not observed
within bone in the absence of a cortical break. In prior
pathological studies of gout, researchers have reported
MSU crystal deposition on the surface of bone, within ero-
sion and in intra-osseous locations, and some investigators
have postulated that MSU crystals can form directly within
the Haversian canals of bone [14]. However, this question
has been difficult to address using standard pathological
methods, as analysis of microscopic slides may not allow
assessment of the entire bone surface. The ability of DECT
to reveal both urate deposition and the entire bone in three
dimensions has provided new insight into this question.
Although our analysis does not absolutely exclude the pos-
sibility that MSU crystals can form within bone, our DECT
data strongly support the concept that MSU crystals form
deposits outside bone prior to development of erosion.
The cellular mechanisms of bone erosion can be consid-
ered in the context of these imaging results. Laboratory
studies have demonstrated that MSU crystals can interact
with bone and joint cells both directly and indirectly to pro-
mote bone erosion. Numerous osteoclasts are present at
the interface between bone and tophus in erosive gout, and
MSU crystals promote osteoclastogenesis through interac-
tions with stromal cells [15]. MSU crystal-induced produc-
tion of catabolic enzymes and cytokines that promote
osteoclastogenesis by synovial fibroblasts, macrophages and
chondrocytes may also contribute to bone erosion [16–19].
MSU crystals also directly induce chondrocyte cell death,
which may compromise integrity of cartilage and allow
focal contact of MSU crystals with sub-chondral bone [17].
This analysis has some limitations. We focused only on
the metatarsal heads, and it is possible that different
mechanisms of erosion might occur at other bone sites.
The sites for scoring were selected for analysis on the
basis of high frequency of disease, particularly in the first
metatarsal head. Initial inter-reader reliability testing also
demonstrated that these sites were associated with the
most reproducible scores (data not shown). Consistent
with the epidemiology of gout, most of the participants
were men, and these findings may not be generalizable to
women. DECT does have limitations of detection, and
very small deposits of crystals may not be detected using
this method [20]. Almost all participants were receiving
urate-lowering therapy, with a wide range of serum urate
concentrations at the time of scanning. It is possible that
some patients may have had previous remodelling of urate
deposits or bone erosion following urate-lowering therapy.
To address this issue, the study was designed to include
only sites with urate deposits evident on DECT scans in
the bone analysis. We also acknowledge that the cross-
sectional study design did not allow us to track the pro-
gression of urate deposition and erosion over time. For
this reason, this analysis cannot conclusively prove that
true intra-osseous deposition does not occur as a precur-
sor to erosion. Nevertheless, the lack of any true intra-
osseous deposition in this study of a large number of
joints argues against this possibility.
Conclusions
This systematic DECT analysis examining the three-
dimensional positional relationship between bone and
urate shows that MSU crystals are deposited on the bone
surface and within bone erosion, but not as true intra-
osseous depositions. These data support the concept that
MSU crystals deposit outside bone and then contribute to
bone erosion through an ‘outside-in’ mechanism.
Table 1 Clinical features of study participants
Male sex, n (%) 134 (93.1 %)








Disease duration, mean (SD) 22 (12) years
Number of tophi, median (range) 4.5 (1–41)











Serum urate, mean (SD) 0.40 (0.12) mmol/L
Towiwat et al. Arthritis Research & Therapy  (2016) 18:208 Page 3 of 6
Fig. 2 Example of apparent metatarsal intra-osseous urate deposit in the axial plane, with images in other planes showing urate within an
erosion. Urate is colour-coded as green and bone as purple
Fig. 1 Sagittal images of the metatarsal heads from different patients. Images show examples of (a) urate deposition inside the joint but not in
contact with bone, (b) urate deposition in contact with bone and within an erosion, and (c) urate deposition in contact with bone and on the
surface of bone. Urate is colour-coded as green and bone as purple
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Urate deposit in joint, n (%) (95 % CI) 230 of 288 (79.9 %)
(74.9–84.1 %)
139 of 287 (48.4 %)
(42.7–54.2 %)
101 of 287 (35.2 %)
(29.9–40.9 %)
85 of 287 (29.6 %)
(24.6–35.1 %)
126 of 284 (44.4 %)
(38.7–50.2 %)
681 of 1433 (47.5 %)
(45.0–50.1 %)
Urate deposit in contact with bone,
n (%) (95 % CI)
169 of 230 (73.5 %)
(67.4–78.8 %)
64 of 139 (46.0 %)
(38.0–54.3 %)
38 of 101 (37.6 %)
(28.8–47.4 %)
27 of 85 (32 %)
(23–42 %)
72 of 126 (57.1 %)
(48.4–65.5 %)
370 of 681 (54.3 %)
(50.6–58.0 %)
Urate deposit on bone surface only,
n (%) (95 % CI)
40 of 169 (23.7 %)
(17.9–30.6 %)
39 of 64 (61 %)
(49–72 %)
27 of 38 (71 %)
(52–83 %)
14 of 27 (52 %)
(34–69 %)
23 of 72 (32 %)
(22–43 %)
143 of 370 (38.6 %)
(33.8–43.7 %)a
Urate deposit at site of erosion, n (%)
(95 % CI)
129 of 169 (76.3 %)
(69.4–82.1 %)
25 of 64 (39 %)
(28–51 %)
11 of 38 (28.9 %)
(17–5 %)
13 of 27 (48.1 %)
(31–66 %)
49 of 72 (68.1 %)
(57–78 %)
227 of 370 (61.4 %)
(56.3–66.2 %)a
True intra-osseous urate deposit, n (%)
(95 % CI)
0 of 169 (0 %)
(0–2 %)
0 of 64 (0 %)
(0–6 %)
0 of 38 (0 %)
(0–9 %)
0 of 27 (0 %)
(0–13 %)
0 of 72 (0 %)
(0–4 %)
0 of 370 (0 %)
(0–1 %)a
















DECT: Dual-energy computed tomography; HU: Hounsfield units;
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